This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...

Many Americans have flocked to cheaper, compounded versions of GLP-1 weight loss drugs in lieu of brand-name treatments. That competition is cutting into demand for Novo Nordisk’s prescriptions, a ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

Winfrey opened up about her decision to use a medication to help her lose weight in an interview with People. Her new TV ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

Unfortunately, many patients may choose to forego additional treatments due to the dramatic increase in cost associated with brand name versus compounded GLP-1 drugs. 5. Q. Are any GLP-1s still on ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

GLP-1 injections, such as semaglutide and tirzepatide products like Ozempic, Wegovy, Mounjaro and Zepbound have led many consumers to spend significantly less money on food — both at grocery stores ...